{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:43:38Z","timestamp":1790052218869,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11030-023-10792-7","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T04:46:07Z","timestamp":1706157967000},"page":"4017-4049","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sulfonamido, amido heterocyclic adducts of tetrazole derivatives as BACE1 inhibitors: in silico exploration"],"prefix":"10.1007","volume":"28","author":[{"given":"Nachiket","family":"Joshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajasekhar Reddy","family":"Alavala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"10792_CR1","unstructured":"2023 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s & Dementia.; Available from: https:\/\/www.alz.org"},{"key":"10792_CR2","doi-asserted-by":"publisher","unstructured":"Maia MA, Sousa E. BACE-1, and \u03b3-secretase as therapeutic targets for Alzheimer\u2019s disease (2019). Vol. 12(1):41, Pharmaceuticals. MDPI AG; Available from: https:\/\/doi.org\/10.3390\/ph12010041","DOI":"10.3390\/ph12010041"},{"key":"10792_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd000202","author":"N Qizilbash","year":"2007","unstructured":"Qizilbash N, Birks J, L\u00f3pez Arrieta J, Lewington S, Szeto S, WITHDRAWN: Tacrine for Alzheimer\u2019s disease, (2007) 3, Cochrane Database of Systematic Reviews, Cochrane Library. Available from. https:\/\/doi.org\/10.1002\/14651858.cd000202","journal-title":"Available from"},{"key":"10792_CR4","doi-asserted-by":"publisher","unstructured":"Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer\u2019s disease drug development pipeline: 2023 (2023), Vol. 9(2):e12385, Alzheimer\u2019s Dementia, Wiley; Available from: https:\/\/doi.org\/10.1002\/trc2.12385","DOI":"10.1002\/trc2.12385"},{"key":"10792_CR5","doi-asserted-by":"publisher","unstructured":"Alhazmi HA, Albratty M. An update on the novel and approved drugs for Alzheimer's disease (2022), Vol. 30 (12), Saudi Pharmaceutical Journal. Elsevier B.V.; Available from: https:\/\/doi.org\/10.1016\/j.jsps.2022.10.004","DOI":"10.1016\/j.jsps.2022.10.004"},{"key":"10792_CR6","doi-asserted-by":"publisher","unstructured":"Brockmann R, Nixon J, Love BL, Yunusa I. Impacts of FDA approval and Medicare restriction on anti-amyloid therapies for Alzheimer\u2019s disease: patient outcomes, healthcare costs, and drug development (2023), Vol. 20 (100467), Lancet Regional Health - Americas. Elsevier Ltd; Available from: https:\/\/doi.org\/10.1016\/j.lana.2023","DOI":"10.1016\/j.lana.2023"},{"key":"10792_CR7","doi-asserted-by":"publisher","unstructured":"Verger A, Yakushev I, Albert NL, van Berckel B, Brendel M, Cecchin D, et al. FDA approval of lecanemab: the real start of widespread amyloid PET use? \u2014 the EANM Neuroimaging Committee perspective (2023), Vol. 50, European Journal of Nuclear Medicine and Molecular Imaging. Springer Science and Business Media Deutschland GmbH; Available from: https:\/\/doi.org\/10.1007\/s00259-023-06177-5","DOI":"10.1007\/s00259-023-06177-5"},{"key":"10792_CR8","doi-asserted-by":"publisher","unstructured":"Sun J, Roy S. The physical approximation of APP and BACE-1: A key event in Alzheimer\u2019s disease pathogenesis (2018), Vol. 78 (3), Developmental Neurobiology. John Wiley and Sons Inc.; Available from: https:\/\/doi.org\/10.1002\/dneu.22556","DOI":"10.1002\/dneu.22556"},{"key":"10792_CR9","doi-asserted-by":"publisher","unstructured":"Cole SL, Vassar R. The Alzheimer\u2019s disease \u03b2-secretase enzyme, BACE1 (2007), Vol. 2 (22), Molecular Neurodegeneration, BioMed Central; Available from: https:\/\/doi.org\/10.1186\/1750-1326-2-22","DOI":"10.1186\/1750-1326-2-22"},{"key":"10792_CR10","doi-asserted-by":"publisher","unstructured":"Gehlot P, Kumar S, Kumar Vyas V, Singh Choudhary B, Sharma M, Malik R. Guanidine-based \u03b2 amyloid precursor protein cleavage enzyme 1 (BACE-1) inhibitors for the Alzheimer\u2019s disease (AD): A review (2022), Vol. 74:117047, Bioorganic Medicinal Chemistry, Elsevier; Available from: https:\/\/doi.org\/10.1016\/j.bmc.2022.117047","DOI":"10.1016\/j.bmc.2022.117047"},{"key":"10792_CR11","doi-asserted-by":"publisher","unstructured":"Munj SM, Patil PB. Drug Discovery to Drug Development of BACE1 Inhibitor as Anti-Alzheimer\u2019s: A Review (2022), Vol. 23(2), Current Topics in Medicinal Chemistry, Bentham Sciences; Available from: https:\/\/doi.org\/10.2174\/1568026623666221228140450","DOI":"10.2174\/1568026623666221228140450"},{"key":"10792_CR12","doi-asserted-by":"publisher","unstructured":"Miranda A, Montiel E, Ulrich H, Paz C, Ferreira S. Selective Secretase Targeting for Alzheimer\u2019s Disease Therapy (2021), Vol. 81 (1), Journal of Alzheimer\u2019s Disease, IOS Press BV; Available from: https:\/\/doi.org\/10.3233\/JAD-201027","DOI":"10.3233\/JAD-201027"},{"key":"10792_CR13","doi-asserted-by":"publisher","unstructured":"Oehlrich D, Peschiulli A, Tresadern G, Van Gool M, Vega JA, De Lucas AI, et al. Evaluation of a Series of \u03b2-Secretase 1 Inhibitors Containing Novel Heteroaryl-Fused-Piperazine Amidine Warheads (2018), Vol. 10(8), ACS Medicinal Chemistry Letters, American Chemical Society; Available from: https:\/\/doi.org\/10.1021\/acsmedchemlett.9b00181","DOI":"10.1021\/acsmedchemlett.9b00181"},{"key":"10792_CR14","doi-asserted-by":"publisher","unstructured":"Das B, Yan R. A Close Look at BACE1 Inhibitors for Alzheimer\u2019s Disease Treatment (2019), Vol. 33 (3), CNS Drugs, Springer International Publishing; Available from: https:\/\/doi.org\/10.1007\/s40263-019-00613-7","DOI":"10.1007\/s40263-019-00613-7"},{"key":"10792_CR15","doi-asserted-by":"publisher","unstructured":"Rombouts F, Kusakabe K ichi, Hsiao CC, Gijsen HJM. Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020) (2021), Vol. 31 (1), Expert Opinion on Therapeutic Patents, Taylor and Francis Ltd.; Available from: https:\/\/doi.org\/10.1080\/13543776.2021.1832463","DOI":"10.1080\/13543776.2021.1832463"},{"key":"10792_CR16","doi-asserted-by":"publisher","unstructured":"Zou Y, Li L, Chen W, Chen T, Ma L, Wang X, et al. Virtual screening and structure-based discovery of indole acyl guanidines as potent \u03b2-secretase (BACE1) inhibitors (2013), Vol. 18(5):5706\u201322, Molecules, MDPI; Available from: https:\/\/doi.org\/10.3390\/molecules18055706","DOI":"10.3390\/molecules18055706"},{"key":"10792_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8934289","author":"S Ali","year":"2020","unstructured":"Ali S, Bin AMHH, Khan F, Murtaza G, Rizvanov AA, Iqbal J, Evaluation B, of Newly Synthesized Biaryl Guanidine Derivatives to Arrest \u03b2 -Secretase Enzymatic Activity Involved in Alzheimer\u2019s Disease, et al (2020) Article number 8934289, BioMed Research International. Hindawi; Available from. https:\/\/doi.org\/10.1155\/2020\/8934289","journal-title":"Hindawi; Available from"},{"key":"10792_CR18","doi-asserted-by":"publisher","unstructured":"Polg\u00e1r T, Keser\u00fc GM. Virtual screening for \u03b2-secretase (BACE1) inhibitors reveals the importance of protonation states at Asp32 and Asp228 (2005), Vol. 48(11), Journal of Medicinal Chemistry, American Chemical Society; Available from: https:\/\/doi.org\/10.1021\/jm049133b","DOI":"10.1021\/jm049133b"},{"key":"10792_CR19","doi-asserted-by":"publisher","unstructured":"Liu S, Fu R, Cheng X, Chen SP, Zhou LH. Exploring the binding of BACE-1 inhibitors using comparative binding energy analysis (COMBINE) (2012), Vol. 12 (21), BMC Structural Biology, BioMed Central; Available from: https:\/\/doi.org\/10.1186\/1472-6807-12-21","DOI":"10.1186\/1472-6807-12-21"},{"key":"10792_CR20","doi-asserted-by":"publisher","unstructured":"Tuccinardi T. What is the current value of MM\/PBSA and MM\/GBSA methods in drug discovery? (2021), Vol. 16 (11), Expert Opinion on Drug Discovery, Taylor and Francis Ltd.; Available from: https:\/\/doi.org\/10.1080\/17460441.2021.1942836","DOI":"10.1080\/17460441.2021.1942836"},{"key":"10792_CR21","doi-asserted-by":"publisher","unstructured":"Ongaro A, Oselladore E, Memo M, Ribaudo G, Gianoncelli A. Insight into the LFA-1\/SARS-CoV-2 Orf7a Complex by Protein-Protein Docking, Molecular Dynamics, and MM-GBSA Calculations (2021), Vol. 61(6), Journal of Chemical Information and Modeling, American Chemical Society; Available from: https:\/\/doi.org\/10.1021\/acs.jcim.1c00198","DOI":"10.1021\/acs.jcim.1c00198"},{"key":"10792_CR22","doi-asserted-by":"publisher","unstructured":"Basnet S, Ghimire MP, Lamichhane TR, Adhikari R, Adhikari A. Identification of potential human pancreatic \u03b1amylase inhibitors from natural products by molecular docking, MM\/GBSA calculations, MD simulations, and ADMET analysis (2023), Vol. 18(3):e0275765 PLOS ONE; Available from: https:\/\/doi.org\/10.1371\/journal.pone.0275765","DOI":"10.1371\/journal.pone.0275765"},{"key":"10792_CR23","doi-asserted-by":"publisher","unstructured":"Zhao J, Liu X, Xia W, Zhang Y, Wang C. Targeting Amyloidogenic Processing of APP in Alzheimer\u2019s Disease (2020), Vol. 13, Frontiers in Molecular Neuroscience, Frontiers Media S.A.; Available from: https:\/\/doi.org\/10.3389\/fnmol.2020.00137","DOI":"10.3389\/fnmol.2020.00137"},{"key":"10792_CR24","doi-asserted-by":"publisher","unstructured":"Zhang X, Song W. The role of APP and BACE1 trafficking in APP processing and amyloid-\u03b2 generation (2013), Vol. 5 (46), Alzheimer\u2019s research and Therapy, BioMed Central, Available from: https:\/\/doi.org\/10.1186\/alzrt211","DOI":"10.1186\/alzrt211"},{"key":"10792_CR25","doi-asserted-by":"publisher","unstructured":"Das B, Yan R. A Close Look at BACE1 Inhibitors for Alzheimer\u2019s Disease Treatment (2019), Vol. 33 (3), CNS Drugs. Springer International Publishing; Available from: https:\/\/doi.org\/10.1007\/s40263-019-00613-7","DOI":"10.1007\/s40263-019-00613-7"},{"key":"10792_CR26","doi-asserted-by":"publisher","unstructured":"Ghosh AK, Osswald HL. BACE1 (\u03b2-secretase) inhibitors for the treatment of Alzheimer\u2019s disease (2014), Vol. 43 (19), Chemical Society Reviews. Royal Society of Chemistry; Available from: https:\/\/doi.org\/10.1039\/c3cs60460h","DOI":"10.1039\/c3cs60460h"},{"key":"10792_CR27","doi-asserted-by":"publisher","unstructured":"Barman A, Prabhakar R. Elucidating the catalytic mechanism of \u03b2-secretase (BACE1): A quantum mechanics\/molecular mechanics (QM\/MM) approach, Vol. 40, Journal of Molecular Graphics and Modeling, Elsevier; Available from: https:\/\/doi.org\/10.1016\/j.jmgm.2012.12.010","DOI":"10.1016\/j.jmgm.2012.12.010"},{"key":"10792_CR28","doi-asserted-by":"publisher","unstructured":"Yen YC, Kammeyer AM, Jensen KC, Tirlangi J, Ghosh AK, Mesecar AD. Development of an Efficient Enzyme Production and Structure-Based Discovery Platform for BACE1 Inhibitors HHS Public Access (2019), Vol. 58(44), Biochemistry, American Chemical Society; Available from: https:\/\/doi.org\/10.1021\/acs.biochem.9b00714","DOI":"10.1021\/acs.biochem.9b00714"},{"key":"10792_CR29","doi-asserted-by":"publisher","unstructured":"Mouchlis VD, Melagraki G, Zacharia LC, Afantitis A. Computer-aided drug design of \u03b2-secretase, \u03b3- secretase and anti-tau inhibitors for the discovery of novel Alzheimer\u2019s therapeutics (2020), Vol. 21 (3), International Journal of Molecular Sciences, MDPI AG; Available from: https:\/\/doi.org\/10.3390\/ijms21030703","DOI":"10.3390\/ijms21030703"},{"key":"10792_CR30","doi-asserted-by":"publisher","unstructured":"Cosconati S, Marinelli L, Di Leva FS, La Pietra V, De Simone A, Mancini F, et al. Protein flexibility in virtual screening: The BACE-1 case study (2012), Vol. 52(10), Journal of Chemical Information and Modeling, American Chemical Society; Available from: https:\/\/doi.org\/10.1021\/ci300390h","DOI":"10.1021\/ci300390h"},{"key":"10792_CR31","doi-asserted-by":"publisher","unstructured":"Xu Y, Li MJ, Greenblatt H, Chen W, Paz A, Dym O, et al. Flexibility of the flap in the active site of BACE1 as revealed by crystal structures and molecular dynamics simulations (2012), Vol. 68 (1), Acta Crystallographica Section D Biological Crystallography, International Union of Crystallography; Available from: https:\/\/doi.org\/10.1107\/s0907444911047251","DOI":"10.1107\/s0907444911047251"},{"key":"10792_CR32","doi-asserted-by":"publisher","unstructured":"Shimizu H, Tosaki A, Kaneko K, Hisano T, Sakurai T, Nukina N. Crystal Structure of an Active Form of BACE1, an Enzyme Responsible for Amyloid \u03b2 Protein Production (2008), Vol. 28 (11), Molecular and Cellular Biology, Taylor and Francis; Available from: https:\/\/doi.org\/10.1128\/MCB.02185-07","DOI":"10.1128\/MCB.02185-07"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-023-10792-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-023-10792-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-023-10792-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T17:05:53Z","timestamp":1734627953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-023-10792-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10792"],"URL":"https:\/\/doi.org\/10.1007\/s11030-023-10792-7","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]},"assertion":[{"value":"1 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}